Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
3 hedge funds and large institutions have $7.61M invested in Seelos Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
8% more capital invested
Capital invested by funds: $7.07M → $7.61M (+$537K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Callan Capital
La Jolla,
California
|
-$26K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$24K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KF
26
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
CC
29
Callan Capital
La Jolla,
California
| – | -$26K | – | – |
|
|
30
HighTower Advisors
Chicago,
Illinois
| – | -$24K | – | – |
|
|
31
Wolverine Trading
Chicago,
Illinois
| – | -$11K | – | – |
|
SEEL Hedge Fund Activity: Q3 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2016, worth a combined $7.61M — up 7.6% from $7.07M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.6M. The largest seller was Callan Capital, cutting an estimated $26K.
- 3 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2016, up from 2 in Q2 2016.
- Funds reported $7.61M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2016, up 7.6% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2016 and 0 closed out, a net change of +1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2016 was Anson Funds Management, an estimated $1.6M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2016 was Callan Capital, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2016.